Filing Details

Accession Number:
0001140361-17-004975
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-08 08:21:46
Reporting Period:
2017-02-06
Filing Date:
2017-02-08
Accepted Time:
2017-02-08 08:21:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1128189 Protokinetix Inc. PKTX Pharmaceutical Preparations (2834) 943355026
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1621643 Marie Susan Woodward 705 Dugan Road
Belpre OH 45714
Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-06 250,000 $0.04 250,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option $0.05 2020-12-31 4,000,000 4,000,000 Direct
Common Stock Option $0.08 2019-12-31 4,000,000 4,000,000 Direct
Common Stock Option $0.04 2020-02-25 4,000,000 4,000,000 Direct
Common Stock Option $0.04 2020-02-25 2,000,000 2,000,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2020-12-31 4,000,000 4,000,000 Direct
2019-12-31 4,000,000 4,000,000 Direct
2020-02-25 4,000,000 4,000,000 Direct
2020-02-25 2,000,000 2,000,000 Direct
Footnotes
  1. Options issued pursuant to the Company's 2017 Stock Option and Stock Bonus Plan. 1,000,000 shares of common stock vest on March 31, 2017; thereafter 1,000,000 shares vest every three months.
  2. Options issued pursuant to the Company's 2015 Stock Option and Stock Bonus Plan. 1,000,000 shares of common stock vest on March 31, 2016; thereafter 1,000,000 shares vest every three months.
  3. 400,000 shares of common stock vest on March 31, 2015; thereafter 400,000 shares vest monthly on the last day of each month.
  4. This option vests upon a change in control in which the Company receives a price equal to or greater than $0.50 per issued and outstanding share of common stock as defined in Ms. Woodward's Consulting Agreement. On December 30, 2017, the Company extended Ms. Woodward's option expiration date from February 25, 2017 to February 25, 2020.